Early Clinical Trials Show Promise in Shrinking Glioblastoma with CAR-T Therapy

Novel immune cell-based treatments have demonstrated significant tumor reduction in patients with the most aggressive brain cancer, according to recent studies.

Two separate clinical trials, one conducted by researchers at Harvard and another at the University of Pennsylvania, have shown that CAR-T therapy can reduce the size of glioblastoma tumors.
The therapy involves genetically modifying patients' T cells to target cancer more effectively when reintroduced into the body.
In the Harvard study, all nine patients experienced tumor size reduction, with one patient's tumor nearly disappearing five days after treatment.
The University of Pennsylvania's trial involved seven patients, with early results indicating a reduction in tumor size, although long-term effects remain uncertain.
CAR-T therapy, previously successful in treating blood cancers, faces challenges in solid tumors like glioblastoma due to their varied characteristics.

Live Science

Washington Examiner

The Philadelphia Inquirer